AI assistant
BICYCLE THERAPEUTICS PLC — Director's Dealing 2021
Aug 25, 2021
32777_dirs_2021-08-25_b0d5cb06-9d01-4d1e-8377-e2f6c2124ea7.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: BICYCLE THERAPEUTICS plc (BCYC)
CIK: 0001761612
Period of Report: 2021-08-23
Reporting Person: Kalowski Lee (President and CFO)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2021-08-23 | Ordinary Shares | M | 7500 | $1.60 | Acquired | 7500 | Direct |
| 2021-08-23 | Ordinary Shares | S | 7500 | $33.02 | Disposed | 0 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2021-08-23 | Stock Option (Right to Buy) | $1.60 | M | 7500 | Disposed | 2027-07-23 | Ordinary Shares (7500) | Direct |
Footnotes
F1: Shares exercised and sold pursuant to a Rule 10b5-1 trading plan.
F2: This exercise price is in US Dollars and reflects the conversion of GBP to USD at an exchange rate of $1.366815 to GBP 1.00 as of August 23, 2021.
F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.00 to
$33.056 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and
Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this
footnote.
F4: 20% of the shares subject to the option vested on July 24, 2018, 60% of the shares subject to the option will vest each month thereafter in 36
equal monthly installments, and the remaining 20% of the shares subject to the option will vest on the earlier of (i) the fourth anniversary of the
grant date and (ii) the date on which the Issuer's board of directors determines that the Issuer has satisfied certain performance vesting
milestones, in all cases provided that the Reporting Person remains continuously employed with us through each applicable vesting date.